Here's Why Conmed (CNMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Conmed (CNMD) Beat Estimates Again in Its Next Earnings Report?
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain CONMED Stock in Your Portfolio
CNMD is poised for growth with strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
Here's Why Conmed (CNMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
CONMED Corporation (CNMD) Q2 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Curt Hartman – Chair of the Board, President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Pat Beyer – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Robbie Marcus – JPMorgan Dino Weinstock – Wells Fargo Travis Steed – BofA Mike Matson – Needham Kristen Stewart – CL King Operator Good day, and thank you for standing by. Welcome to CONMED's Second Quarter Fiscal 2024 Earnings Conference Call.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Conmed (CNMD) Q2 Earnings Beat Estimates
Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago.
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
